Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab versus zoledronic acid for adjuvant treatment of bone metastasis
ChiCTR2000031557Phase 4Not yet recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jun 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in bone metastases comparing Zoledronic acid group with Denosumab group (2 arms). Primary endpoints: Overall survival, Progression-free survival and 1 more. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
denosumabzoledronic acid
03
Conditions
bone metastases
Beyond the preview
Go deeper on ChiCTR2000031557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031557.